NEW YORK, April 30, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding Omnicare, Inc. (NYSE: OCR), DaVita Healthcare Partners, Inc. (NYSE: DVA), Healthways, Inc. (NASDAQ: HWAY), MEDNAX, Inc. (NYSE: MD) and HealthSouth Corporation (NYSE: HLS). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1804-100free.
Omnicare, Inc. Analyst Notes
On April 23, 2014, Omnicare, Inc. (Omnicare) reported Q1 2014 financial results. In Q1 2014, the Company's net sales increased 7.7% YoY to $1.6 billion. Q1 2014 net income was $63.7 million, or $0.59 per diluted share, compared to $54.4 million, or $0.51 per diluted share, in Q1 2013. For full-year 2014, Omnicare expects revenues in the range of $6.3 billion to $6.4 billion, with adjusted cash EPS of $3.64 to $3.72. The full analyst notes on Omnicare are available to download free of charge at:
DaVita Healthcare Partners, Inc. Analyst Notes
On April 23, 2014, DaVita Healthcare Partners, Inc. (DaVita) announced that its DaVita Kidney Care division has acquired three hemodialysis centers from Sinar Indentiti Sbn Bhd (Sinar Identiti) to expand its care of kidney patients in Malaysia. DaVita Kidney Care stated that the acquisition adds three clinics to its 21 existing centers that span both peninsular and east Malaysia. "DaVita is committed to raising the standard of care for chronic kidney disease patients in Malaysia," said Atul Mathur, President of DaVita Kidney Care in the Asia-Pacific region. "As we continue to seek opportunities to bring DaVita's industry-leading outcomes to chronic kidney disease populations in the country, we believe Malaysia's kidney patients ultimately benefit." The full analyst notes on DaVita are available to download free of charge at:
Healthways, Inc. Analyst Notes
On April 24, 2014, Healthways, Inc. (Healthways) reported Q1 2014 financial results. In Q1 2014, the Company's revenues totaled $176.8 million, up 7% YoY. Q1 2014 net loss was $9.6 million, or $0.27 loss per diluted share, compared to a net loss of $3.9 million, or $0.12 loss per diluted share, in Q1 2013. "Our financial results for the first quarter of 2014 are consistent with our expectations for the quarter and our financial guidance for the year," said Ben R. Leedle, Jr., President and CEO of Healthways. For full-year 2014, the Company expects revenues of $730.0 million to $760.0 million. The full analyst notes on Healthways are available to download free of charge at:
MEDNAX, Inc. Analyst Notes
On April 21, 2014, MEDNAX, Inc. (MEDNAX) announced the acquisition of Fredericksburg Anesthesia Associates, Inc. (Fredericksburg Anesthesia Associates). MEDNAX stated that the acquisition is expected to enable Fredericksburg Anesthesia Associates to become part of the Company's American Anesthesiology division. Further, MEDNAX informed that the acquisition is a cash transaction and is expected to be immediately accretive to earnings. The full analyst notes on MEDNAX are available to download free of charge at:
HealthSouth Corporation Analyst Notes
On April 23, 2014, HealthSouth Corporation (HealthSouth) announced that it has signed an agreement with Mountain States Health Alliance to form a joint venture to own and operate the James H. & Cecile C. Quillen Rehabilitation Hospital in Johnson City, Tennessee. The Companies expect to finalize the joint venture by the end of 2014. The full analyst notes on HealthSouth are available to download free of charge at:
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review